4WM
BCYC

49 Wealth Management’s Bicycle Therapeutics BCYC Stock Holding History

49 Wealth Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,317
Closed -$66.4K – 202
2026
Q1 		$66.4K Buy
+14,317
New +$81.8K 0.01% 198

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

49 Wealth Management's BCYC Position: Q2 2026 in Review

49 Wealth Management sold out of Bicycle Therapeutics (BCYC) in Q2 2026, closing a stake of 14,317 shares — an estimated $66.4K sold.

49 Wealth Management first reported a position in BCYC in Q1 2026 and held it in 1 quarter. The position peaked at $66.4K in Q1 2026. 103 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • 49 Wealth Management reported no remaining Bicycle Therapeutics position as of Q2 2026 after selling out during the quarter.
  • 49 Wealth Management sold 14,317 Bicycle Therapeutics shares in Q2 2026, an estimated $66.4K.
  • 49 Wealth Management first reported a position in Bicycle Therapeutics in Q1 2026 and held it in 1 quarter.
  • 49 Wealth Management's Bicycle Therapeutics position peaked at $66.4K in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on 49 Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.